SC 13D/A

                       UNITED STATES
           SECURITIES AND EXCHANGE COMMISSION
                   Washington, D.C. 20549

                        SCHEDULE 13D

         Under the Securities Exchange Act of 1934
                     (Amendment No.  5)*

                         LABONE, INC.
                      (Name of Issuer)

               Common Stock $.01 Par Value (1)
                (Title of Class of Securities)

                         505 40 E 101
                        (CUSIP Number)

       Lathrop M. Gates, 2345 Grand Blvd., Suite 2800,
           Kansas City, MO  64108, (816) 292-2000
        (Name, Address and Telephone Number of Person
      Authorized to Receive Notices and Communications)

                           07/01/97
   (Date of Event which Requires Filing of this Statement)

If the reporting person has previously filed a statement on 
Schedule 13G to report the acquisition which is the subject of 
this Schedule 13D, and is filing this schedule because of Rule 
13d-1(b) (3) or (4), check the following box.  ______

Check the following box if a fee is being paid with this 
statement.  ______ (A fee is not required only if the reporting 
person: (1) has a previous statement on file reporting 
beneficial ownership of more than five percent of the class of 
securities described in Item 1; and (2) has filed no amendment 
subsequent thereto reporting beneficial ownership of five 
percent or less of such class.)  (See Rule 13d-7).

Note:  Six copies of this statement, including all exhibits, 
should be filed with the Commission.  See Rule 13d-1 (a) for 
other parties to whom copies are to be sent.

                                                   
____________________
*The remainder of this cover page shall be filled out for a 
reporting person's initial filing on this form with respect to 
the subject class of securities, and for any subsequent 
amendment containing information which would alter the 
disclosures provided in a prior cover page.


The information required on the remainder of this cover page 
shall not be deemed to be "filed" for the purpose of Section 18 
of the Securities Exchange Act of 1934 ("Act") or otherwise 
subject to the liabilities of that section of the Act but shall 
be subject to all other provisions of the Act (however, see the 
Notes).




(1)     Name of Reporting Person
          S.S. or I.R.S. Identification No. of Above Person

          Seafield Capital Corporation
          43-1039532

(2)     Check the Appropriate Box               (a)______   
          if a Member of a Group*               (b)______

(3)     SEC Use Only

(4)     Source of funds*
          WC

(5)     Check Box if Disclosure of Legal Proceedings is 
          Required Pursuant to Items 2(d) or 2(e)  ______

(6)      Citizenship or Place of Organization
           Missouri

           Number of Shares            (7)     Sole Voting Power
           beneficially Owned                  10,712,200
           by Each Reporting
           Person With                 (8)     Shared Voting Power
                                               -0-

                                        (9)    Sole Dispositive Power
                                               10,712,200
                                                              
                                       (10)    Shared Dispositive Power
                                               -0-

(11)     Aggregate Amount Beneficially Owned By Each Reporting Person
            10,712,200

(12)     Check Box if the Aggregate Amount in Row (11) Excludes
         Certain Shares*              __X___


(13)     Percent of Class Represented by Amount in  Row (11) 
         81.7%

(14)     Type of Reporting Person*       
         CO  

*  See Instructions before Filling Out!



Item 1.      Security and Issuer.

This Amendment No. 5 ("Amendment No. 5") to  
Schedule 13D concerns the common stock, par value $.01 per 
share ("Common Stock") of LabOne, Inc. ("LabOne"), whose 
principal executive offices are at 10310 West 84th Terrace, 
Lenexa, Kansas 66214.  Amendment No. 5 amends an original 
report (the "Original Report") on Schedule 13D filed November 
29, 1990 respecting Home Office Reference Laboratory, Inc., the 
former name of LabOne, as such Original Report has been amended 
by Amendment No. 1 to Schedule 13D, dated January 28, 1991 
("Amendment No. 1"), Amendment No. 2 to Schedule 13D, dated 
February 17, 1992 ("Amendment No. 2"), Amendment No. 3 to 
Schedule 13D, dated December 2, 1993 ("Amendment No. 3") and 
Amendment No. 4 to Schedule 13 D, dated February 21, 1995 
("Amendment No. 4") (collectively, Amendments No. 1, No. 2, No. 
3 and No. 4 are sometimes referred to as the "Prior 
Amendments").

Item 2.    Identity and Background.

This report is filed by Seafield Capital Corporation 
("Seafield") (formerly named BMA Corporation).  Seafield is a 
Missouri corporation; the address of its principal executive 
office is 5000 West 95th Street, Suite 260, P.O. Box 7568, 
Shawnee Mission, Kansas 66207.  Seafield is a holding company 
engaged through its subsidiaries in various activities.  Its 
principal interests are its ownership position in LabOne, a 
provider of clinical, substance abuse and insurance laboratory 
testing services, and its 67% ownership of the common stock of 
Response Oncology, Inc. ("Response").  Response is a Tennessee 
corporation the common stock of which is quoted on the national 
market system of the NASDAQ stock market.  Response is a 
comprehensive cancer management company, providing advanced 
cancer treatment services through out-patient facilities under 
the direction of independent oncologists, managing the 
practices of certain oncologists and conducting clinical cancer 
research on behalf of pharmaceutical manufacturers.  On July 1, 
1997, Seafield announced that its Board of Directors had 
decided to distribute all Response common stock owned by 
Seafield to Seafield's shareholders.  On March 3, 1997, 
Seafield distributed to its shareholders all shares of a 
subsidiary company (i.e., SLH Corporation) which now owns all 
of those oil and gas, real estate and venture capital 
investments previously owned by Seafield.

By means of a press release issued February 10, 1995 
Seafield announced that it has retained a financial advisor to 
assist it in considering strategic alternatives to maximize 
shareholder value.  One alternative that Seafield expected to 
consider was a merger of Seafield into LabOne.  By press 
release issued July 1, 1997, Seafield announced that its Board 
of Directors had determined to terminate merger discussions 
with LabOne.  A copy of that later press release is attached as 
an exhibit.

Set forth in Schedule 1 hereto are the names, business 
addresses and principal occupations or employment of the 
executive officers and directors of Seafield.  Each person 
listed on Schedule 1 is a United States citizen.

During the past five years, neither Seafield, nor to its  
knowledge, any of the persons identified in Schedule 1 has been 
(i) convicted in a criminal proceeding, or (ii) a party to a 
civil proceeding of a judicial or administrative body as a 
result of which such person was or is subject to  a judgment, 
decree or final order enjoining future violations of, or 
prohibiting or mandating activities subject to, federal or 
state securities laws or finding any violation with respect to 
such laws. 

Item 3.     Source and Amount of Funds or Other Consideration.

No Amendment to this item.

Item 4.     Purpose of the Transaction.

Seafield stated in the Original Report and the Prior 
Amendments that, subject to certain qualifications set forth in 
the Prior Amendments, it had no plans or proposals which relate 
to or would result in (i) the acquisition by any person of 
additional securities of LabOne, or the disposition of 
securities of LabOne; (ii) an extraordinary corporate 
transaction involving LabOne or any of its subsidiaries; (iii) 
a sale or transfer of a material amount of assets of LabOne or 
any of its subsidiaries; (iv) any change in the present board 
of directors or management of LabOne; (v) any material change 
in the present capitalization or dividend policy of LabOne; 
(vi) any other material change in LabOne's business or 
corporate structure; (vii) any change in LabOne's charter or 
bylaws which may impede the acquisition of control of LabOne by 
any person; (viii) causing a class of LabOne's securities to be 
delisted from a national securities exchange or cease to be 
authorized to be quoted in an inter-dealer quotation system of 
a registered national securities association; (ix) a class of 
equity securities of LabOne being eligible for termination of 
registration pursuant to Section 12(g)(4) of the Exchange Act; 
or (x) any act similar to those enumerated above.

The statements in the preceding paragraph remain accurate. 
As described in the July 1, 1997 Press Release attached hereto 
as an exhibit, Seafield has terminated merger discussions with 
LabOne.

Item 5.     Interest in Securities of the Issuer.

           (a), (b) and (c)

At present and as previously reported in the Original 
Report and the Prior Amendments, Seafield beneficially owns  
10,712,200 shares of LabOne Common Stock.  Seafield has sole 
power to vote and dispose of all of such shares.  Seafield 
acquired all of said shares for investment purposes.

The number of shares beneficially owned by Seafield 
constitutes approximately 81.7% of LabOne's Outstanding Common 
Stock, calculated in accordance with Exchange Act Rule 13d-
3(d)(1).  This percentage does not reflect shares subject to 
issue upon exercise of stock options presently outstanding and 
owned by persons other than Seafield.

Certain of the persons named in Schedule 1 are known 
by Seafield to beneficially own shares of LabOne Common Stock. 
To Seafield's knowledge, these shares were acquired by such 
persons solely for investment purposes and  such persons have 
sole power to vote and dispose of such shares.  Seafield 
disclaims any beneficial ownership in any of such shares.  The 
persons known to Seafield to beneficially own such shares and 
the number of such shares beneficially owned by such persons 
(with an indication of the shares which there is a right to 
acquire) are as follows:

     Name                          Number of Shares

William D. Grant			37,639
W. Thomas Grant, II			29,231
P. Anthony Jacobs			23,500
Steven K. Fitzwater			     5
James R. Seward			        11,800

Beneficial ownership of shares of Common Stock by the 
foregoing individuals includes the following number of shares 
which such persons have rights to acquire pursuant to stock 
options which either are presently exercisable or become 
exercisable within 60 days: William D. Grant 22,000; W. Thomas 
Grant, II, 27,431; P. Anthony Jacobs, 22,000; and James R. 
Seward, 8,800.

No transaction in shares of LabOne Common Stock were 
effected during the past 60 days by Seafield or, to its 
knowledge, any of the persons named in Schedule 1.

(d) and (e)     Not Applicable.

Item 6.     Contracts, Arrangements, Understanding or 
Relationships with Respect to Securities of the Issuer.

None.

Item 7.     Exhibits.

99.1	Press Release dated July 1, 1997




SIGNATURE

After reasonable inquiry and to the best of my knowledge 
and belief, I certify that the information set forth in this 
statement is true, complete and correct.


SEAFIELD CAPITAL CORPORATION


By:      /s/  Steven K. Fitzwater                
Steven K. Fitzwater, Vice President


Date:	July 10, 1997
           

         






       

SCHEDULE 1


Directors of Seafield Capital Corporation

Name, Occupation and Business Address

Lan C. Bentsen, Managing Partner 
Remington Partners (investments)
3040 Post Oak Boulevard, Suite 200
Houston, Texas  77056

John C. Gamble, Managing Partner
Allen, Matkins Leck, Gamble and Mallory (law)
18400 Von Karmen, 4th Floor
Irvine, California  92715

William D. Grant, Retired
One Ward Parkway,  Suite 130
Kansas City, Missouri  64112

W. Thomas Grant, II, Chairman of the Board and Chief Executive 
Officer/Seafield Capital Corporation; Chairman of the Board, 
President and Chief Executive Officer/LabOne, Inc.
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

Michael E. Herman, Chairman
Ewing Marion Kauffman Foundation
4900 Oak Street
Kansas City, Missouri  64112

P. Anthony Jacobs, President and Chief Operating Officer
Seafield Capital Corporation
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

David W. Kemper, Chairman, President and Chief Executive 
Officer
Commerce Bancshares, Inc. (banking)
1000 Walnut Street, 18th Floor
Kansas City, Missouri  64106


John H. Robinson, Jr., Managing Partner
Black & Veatch (design and construction)
11401 Lamar Avenue
Overland Park, Kansas  66211-1598

James R. Seward, Executive Vice President and Chief Financial 
Officer
Seafield Capital Corporation
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

Dennis R. Stephen, Chief Operating Officer
Tennessee Farmers Insurance Companies (insurance)
Post Office Box 307
Columbia, Tennessee  38401

          Executive Officers of Seafield Capital Corporation

           Name,  Position and Business Address

W. T. Grant, II
Chairman of the Board and Chief Executive Officer/Seafield 
Capital Corporation
Chairman of the Board, President and Chief Executive 
Officer/LabOne, Inc.
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

P. Anthony Jacobs, President and Chief Operating Officer
Seafield Capital Corporation
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

James R. Seward, Executive Vice President and Chief Financial 
Officer
Seafield Capital Corporation
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

Steven K. Fitzwater, Vice President, Chief Accounting Officer 
and Secretary
Seafield Capital Corporation
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

Joseph T. Clark, President and Chief Executive Officer
Response Oncology, Inc.
1775 Moriah Woods Boulevard
Memphis, Tennessee  38117

EXHIBIT INDEX


99.1	Press Release dated July 1, 1997

EX-99.1

                                                      EXHIBIT 99.1




FOR IMMEDIATE RELEASE:

					Contacts:  Jim Seward
July 1, 1997                                       Kim Schaefer
	              

SEAFIELD CAPITAL CORPORATION ANNOUNCES TERMINATION
OF MERGER DISCUSSIONS WITH LABONE, Inc. 
               
KANSAS CITY, MO -  Seafield Capital Corporation (Seafield) announced 
today that discussions between Seafield and its 82%-owned subsidiary, 
LabOne, Inc., regarding a possible merger between the two companies have 
been terminated.  In February 1995, Seafield had announced that among the 
strategic alternatives which Seafield expected to pursue was a merger of 
Seafield into LabOne.  Following the transfer of many of Seafield's 
assets to SLH Corporation and the distribution of all SLH Corporation 
stock to Seafield's shareholders earlier this year, Seafield and LabOne 
began discussing a possible merger.  It was also contemplated at the time 
initial merger discussions began that Seafield would distribute its 
Response Oncology holdings to shareholders.  Such distribution is now 
expected to be effected in late July. 

Following the distribution of SLH and Response shares to Seafield 
shareholders, the remaining Seafield assets will consist only of 
approximately $5 million in cash and 10,712,200 LabOne shares.  

As the merger discussions proceeded, Seafield and LabOne were advised 
that any combination of the two companies would result in the surviving 
entity having a significant amount of additional annual amortization 
expense.  Seafield has concluded that the benefits of combining the two 
companies at this time do not justify the additional amortization and the 
resulting adverse impact on earnings.  Accordingly, merger discussions 
between Seafield and LabOne have been terminated.

In light of this development and the expected distribution to Seafield's 
shareholders of all shares of Response Oncology, Inc. common stock owned 
by Seafield, Seafield intends to promptly determine an appropriate 
corporate and expense structure, given that virtually all of its assets 
will consist of its LabOne stock ownership.

LabOne operates a centralized laboratory in the Kansas City area which 
markets clinical, substance abuse and insurance laboratory testing 
services in the United States and Canada.  The common stock of LabOne is 
traded on the National Market System of the Nasdaq Stock Market under the 
symbol "LABS ."